By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    improving patient experience
    6 Ways to Improve Patient Satisfaction Within Hospitals
    December 1, 2021
    degree for healthcare job
    What Are The Health Benefits Of Having A Degree?
    March 9, 2022
    custom software development is changing healthcare
    Digital Customer Journey Mapping and its Importance for Healthcare
    July 21, 2022
    Latest News
    Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
    May 16, 2025
    Learn how to Renew your Medical Card in West Virginia
    May 16, 2025
    Choosing the Right Supplement Manufacturer for Your Brand
    May 1, 2025
    Engineering Temporary Hospitals for Extreme Weather
    April 24, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Can Thinking Younger Make You Live Longer?
    April 20, 2011
    Image
    Obesity’s Outlook Unchanged
    June 13, 2011
    When It’s An Emergency Elderly Not Treated As Well in Hospitals
    July 16, 2011
    Latest News
    Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
    May 18, 2025
    The Critical Role of Healthcare in Personal Injury Recovery: A Comprehensive Guide for Victims
    May 14, 2025
    The Backbone of Successful Trials: Clinical Data Management
    April 28, 2025
    Advancing Your Healthcare Career through Education and Specialization
    April 16, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Pharmacy Trends | Top 5 Pharmacy Trends for 2016
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Global Healthcare > Pharmacy Trends | Top 5 Pharmacy Trends for 2016
Global HealthcareHealth ReformPolicy & Law

Pharmacy Trends | Top 5 Pharmacy Trends for 2016

DanyellJones
Last updated: January 15, 2016 8:28 pm
DanyellJones
Share
10 Min Read
SHARE

Top 5 Pharmacy Trends: Pharmacy Industry Trends and Events

2015 has been an extraordinary year for the Pharmacy Industry complete with reimbursement changes, regulatory changes, new drug approvals, and even political changes.  At the beginning of the year, we thought that it was worthwhile to take a look at 5 Pharmacy Trends and events that are still going to be very relevant as we begin 2016.

Contents
Top 5 Pharmacy Trends: Pharmacy Industry Trends and EventsTop 5 Pharmacy Trends: Pharmacy Industry Trends and EventsTrend OneTrend TwoTrend ThreeTrend FourTrend Five

Top 5 Pharmacy Trends: Pharmacy Industry Trends and Events

2015 has been an extraordinary year for the Pharmacy Industry complete with reimbursement changes, regulatory changes, new drug approvals, and even political changes.  At the beginning of the year, we thought that it was worthwhile to take a look at 5 Pharmacy Trends and events that are still going to be very relevant as we begin 2016. As such, we turned to our favorite pharmacy industry resource, Pharmacy Practice News, to gather intelligence on the latest in pharmacy industry trends and events:

Trend One

Pharmacists Prove Valuable Partners in Reducing Hospital Re-admissions

The University of North Carolina Internal Medicine Clinic reduced its 30-day re-admissions by approximately 65 percent by implementing a care-based follow-up program.  This was an important study which conclusively showed how clinical pharmacists prove invaluable partners in reducing hospital utilization and cost.

More Read

Healthcare Technology Showcase and Learning Center in Washington DC
How to Progress Towards a “Prevention-Based Society”
Personalized Prevention, Part II – The Psychology of Engagement
Countdown to the Physician Sunshine Act: Gloomy Days Ahead
Jeb Bush talks a certain amount of sense on health care

Key components of the program included real-time care management, improved access to care and content standardization in a multidisciplinary visit, according to a study on the intervention published in the Journal of General Internal Medicine.

As part of the intervention, clinic-based care managers were responsible for identifying discharged patients, risk-based triaging, scheduling appointments and working with patients to ensure transportation. Also, once discharged, patients were seen by a clinical pharmacist practitioner, who coordinated 60-minute appointments and by an attending physician for a 20-minute appointment.

The focus of the clinical pharmacist practitioner entailed working with the patient to achieve medication adherence goals. The physician performed a physical exam, diagnosed new problems, addressed goals of care and assisted with patient education, according to the study.

To refine the model for improvement, a patient intake questionnaire and note template were developed, which reinforced need for reminder phone calls. The researchers developed charts to measure the program’s progress, including quantity of hospital discharges, time to follow-up in the clinic and number of completed hospital follow-up visits.

Study investigators reported that “9% and 19% of patients who participated in the initiative were readmitted to the hospital with 30 and 90 days of discharge respectively.  In contrast, 26% and 44% of 52 similar patients who were monitored during the same period but did not participate in the initiative were hospitalized within 30 and 90 days of discharge, respectively.”

Trend Two

FDA Approves U.S. Biosimilar

Beginning in Jan. 2015 the FDA Oncologic Drugs Advisory Committee unanimously recommended the approval of the first U.S. biosimilar, filgrastim, for all five indications sought by the company.

This was the first U.S. biosimilar to be considered, and in March 2015 approved, under the FDA’s new biosimilar approval pathway.  The recommendation, and eventual approval was based in part on a pharmacokinetic and pharmacodynamics study in healthy volunteers, which established bioequivalence and a clinical efficacy and safety study in breast cancer patients, which demonstrated the same clinical performance and safety as the reference product.

Committee members said they were impressed that the filgrstim biosimilar had generated nearly 7.5 million patient-exposure days of experience outside the United States, where the drug is marketed under the name Zarzio.

According the Pharmacy Practice News, Deborah K. Armstrong, MD, ODAC chairperson called the data “more detailed analytic analysis than we are used to seeing at the ODAC.”  Post approval in March, Sandoz will be marketing the biosimilar as Zarxio (filgrastim-sndz).  For 2016 organizations can expect to see additional biosimilars progress through the new approval pathway, with an increased emphasis on detailed analytic analysis.

Trend Three

OIG Examines Generic Pricing

As souring prices of certain widely prescribed generic drugs continued to challenge both community and hospital outpatient pharmacies, the Department of Health and Human Services Office of Inspector General (OIG) launched an investigation into the impact of the increases on the Medicare rebate program.

In November Congress announced that it will require generic drug makers under the Medicaid Drug Rebate Program to pay higher rebates if generic prices rise too quickly.

The new penalty for the price increases is included in the bipartisan, two-year budget and debt deal that President Barack Obama signed into law on Nov. 2nd.  Examination of this issue will take place immediately and tracking mechanisms are being put into place.  Organizations should be monitoring this Pharmacy Industry Trend for regulatory and legislative movement, as well as potential penalties for 2016.

Trend Four

21st Century Cures Act – Healthcare Cures, But at What Cost?

In July 2015, the House passed the 21st Century Cures Act, a sweeping piece of legislation aimed at modernizing the American health care research infrastructure.  As part of the bill, annual funding for the stagnating National Institutes of Health budget would see major increases to offset the effect of sequester and other cuts.  The bill also includes a separate allocation of $1.86 Billion a year for five years to create an NIH Innovation Fund to support research for rare, lethal conditions that are in dire need of better and more innovative treatments.

The NIH funding boost was met with nearly universal praise by researchers and clinicians.  Other components of the bill, however triggered widespread ire – none more so than a rule aimed at streamlining the new drug and device approval process.  To accomplish that goal, the bill would allow the FDA to consider nontraditional study designs and analysis that could include clinician, patient, and parent experience as well as secondary end points and biomarkers when approving new products.  Additionally the bill would relax the FDA’s oversight when manufacturers alter the design of an approved device.

As written in the original article in Pharmacy Practice News “I’ve not seen anything like it,” said Thomas J. Moore, a senior scientist of drug safety and policy at ISMP. “Buried in this legislative tome are numerous new loopholes that would allow pharmaceutical companies to avoid the pivotal legal requirement for robust scientific evidence that that each new drug has, in fact, a clinical benefit.”  While the bill is still in review with the Senate, this will be an important piece of legislation for the Pharmacy Industry to track in 2016.

Trend Five

340B Hospitals Imperiled by Federal Ruling

“A federal court ruling on the 340B Drug Pricing Program may jeopardize education and wellness services – especially those provided in rural and other underserved communities across the country” according to an article by Pharmacy Practice News.  The ruling by U.S. District Court Judge Rudolph Contreas, excluded all orphan drugs regardless of their use from the 340B pricing program.

According to the article “This is a major setback for rural hospitals [that] are already struggling to keep their doors open” stated Ted Slafsky, the president and CEO of 340B Health, an organization that represents 340B participants.

“This ruling could likely lead to reduced access to drugs and biologics for rural, cancer, critical-access and dole community hospitals,” added the ASHP’s Christopher Topoleski.  “Without 340B drug discounts, thee facilities will need to make tough decisions about what types of services they are able to perform.”

John Tremble, CFO of St. Croix Regional Medical Center (SCRMC) in St. Croix Falls, Wis., noted how drastic an impact the new ruling could have on the local level. “The non-covered portion of this increased drug cost will reduce fiscal 2016’s operating margin by 30% for SCRMC,” Mr. Tremble said, with the financial hit approaching $350,000 annually, he noted.

With such a swift and decisive decision, and the potentially large financial and economic impact on rural healthcare systems, consumer care, and reimbursement, this will be a pharmacy trend to stay on top of for 2016.

TAGGED:biopharmapharmaceuticalpharmacy
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Clinical Expertise
Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
Health care
May 18, 2025
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
Health
May 15, 2025
Learn how to Renew your Medical Card in West Virginia
Learn how to Renew your Medical Card in West Virginia
Health
May 15, 2025
Dr. Klaus Rentrop Shares Acute Myocardial Infarction heart treatment
Dr. Klaus Rentrop Shares Acute Myocardial Infarction
Cardiology
May 13, 2025

You Might also Like

Devices for the Treatment of Obesity: Modes of Action

April 18, 2011
Artificial IntelligenceGlobal Healthcare

How Will AI Transform Healthcare From Service To Basic Human Right?

January 16, 2020

ACO’s and CMS

July 2, 2011
Artificial IntelligenceHealth careMedical Innovations

Benefits Of The Internet Of Things For Hospitals And Healthcare

April 24, 2019
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?